Pear Therapeutics Plans To Accelerate Reimbursement For Digital Therapeutics With $80M Series D
The company will use the proceeds to market its three FDA-cleared prescription digital therapeutics.
You may also be interested in...
Public Company Edition: Almost halfway through the year, initial public offerings equal nearly three-quarters of the 2020 total. Also, Pardes is one of four new SPAC mergers; HUTCHMED launched an IPO in Hong Kong; and Zentalis, Theravance and BioXcel launched follow-on offerings.
Pear has commercialized FDA-cleared prescription digital therapeutics for substance abuse disorder, opioid use disorder and chronic insomnia and has 14 more in development. CEO Corey McCann explained Pear’s vision for how PDTs can transform health care.
Dexcom is making CGM data available through consumer devices starting with Garmin’s smartwatches and bicycle computers.